Mercury Bio, Inc.

BiotechnologyB2BBiotechnologyDrug Delivery

📍 Santa Fe, New Mexico, United States• Founded 2021

StreetZero Signal 60

Be the first to signal interest

About Mercury Bio, Inc.

Mercury Bio, Inc. is a Santa Fe, New Mexico-based biotechnology company developing a next-generation biomolecular drug delivery platform using a novel system for drug encapsulation in natural vesicles. The technology enhances drug efficacy while reducing side effects by employing cell-specific targeting. It is an immunology-driven company advancing intracellular therapies for neurodegenerative diseases such as Parkinson's and Alzheimer's, with plans for FDA IND approval and strategic partnerships in the biopharmaceutical industry.

LATEST FUNDINGPrivate Placement

$13K

Announced 2026-11-12

TOTAL RAISED$5.88M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Mercury Bio, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2021

HQSanta Fe, New Mexico, United States

Industry

Biotechnology

Investors

Los Alamos National Laboratory New Mexico Consortium New Mexico Economic Development Department

Key highlights

Closed $2M seed round in August 2023 and welcomed new Finance Director John Tomes.
Total funding reached $5.76M-$5.88M across six rounds including grants and venture rounds.
Advancing pipeline for Parkinson's and Alzheimer's with FDA IND preparations.
Launched MB-TIP platform for intracellular targeting in immunotherapy.
Backed by New Mexico research institutions and preparing for Series A.